Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
Date:5/6/2008

31,

2008 2007

Operating expenses:

Research and development $10,478,047 $8,241,804

Marketing 583,702 302,183

General and administrative 2,667,038 1,827,592

Other 28,257 -

Total operating expenses 13,757,044 10,371,579

Loss from operations (13,757,044) (10,371,579)

Other income (expense):

Interest income 550,380 1,031,890

Interest expense (506,856) (220,009)

Other expense (3,395) -

Total other income, net 40,129 811,881

Net loss $(13,716,915) $(9,559,698)

Basic and diluted net loss

per share(1) $(0.42) $(0.34)

Shares used to compute basic

and diluted net loss per

share(1) 32,921,093 28,402,352

(1) As a result of the issuance of 9,240,307 shares of common stock

pursuant to an effective shelf registration in the first quarter of

2008, there is a lack of comparability in the per share amounts

between the 2008 and 2007 periods presented.

CADENCE PHARMACEUTICALS, INC.

(a development stage company)

CONDENSED BALANCE SHEETS

March 31, December 31,

2008 2007

(unaudited)

Assets

Current assets:

Cash and cash equivalents $91,443,447 $55,392,921

Restricted cash 1,981,848 1,981,848

Prepaid expense
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
3. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
4. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
5. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
6. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
7. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
8. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
9. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
11. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 Tianyin Pharmaceutical Inc. (NYSE ... that specializes in the patented biopharmaceutical, modernized traditional Chinese ... provided updates regarding the notice it received on May ... indicating that the Company was below certain of the ... 134 and 1101 of the NYSE MKT Company Guide, ...
(Date:7/30/2015)...  Growth of the U.S. nonprescription market is primarily ... users to the OTC market. Due to an increasingly ... switch activity over the next five years with several ... brands entering the market into existing categories. ... (even those with low to moderate likelihood), the market ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, Inc. ... second Phase III clinical study for Ozenoxacin, a ... Medimetriks owns the exclusive U.S. rights to Ozenoxacin ... conducted at 44 centers with an emphasis on ... aged 2 months and older with a clinical ...
Breaking Medicine Technology:TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... EXETER, N.H.--(BUSINESS WIRE)--Apr 10, 2007 - ... pharmaceutical,company, today announced that its abstract ... 4-Way Crossover,Pharmacokinetic Study of Intranasal Insulin ... Injectable Fast-Acting,Insulin (Humalog(R)), and Saline Nasal ...
... April 10, 2007 /PRNewswire-FirstCall/ -- Kosan,Biosciences Incorporated announced ... preclinical pipeline, including its Hsp90,inhibitor, epothilone and nuclear ... the American Association for Cancer Research,(AACR), being held ... presentations on Kosan's programs are as follows. The,location ...
Cached Medicine Technology:Nasulin Interim Results to Be Presented at American Diabetes,Association Scientific Sessions 2Nasulin Interim Results to Be Presented at American Diabetes,Association Scientific Sessions 3Kosan Announces Data Presentations at Upcoming AACR Annual Meeting 2Kosan Announces Data Presentations at Upcoming AACR Annual Meeting 3
(Date:8/1/2015)... ... , ... On March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for ... by stepping off Springer Mountain and heading north. Since that day, Phil has hiked over ... was greeted by friends and family. He visited CCAR and left an inspirational message ...
(Date:7/31/2015)... ... , ... When the weather turned hot and warm-season turfgrasses, such as zoysia ... Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, both names are ... type of sod, Super-Sod is giving away red Adirondack chairs with the Leisure Time ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable ... on in Chicago at Grant Park. The festival will end on Sunday, August ... to Chicago for the annual Lollapalooza. This unique and unbelievably popular festival attracts ...
(Date:7/31/2015)... ... 2015 , ... Last week, the Mesothelioma Applied Research Foundation ... accessed by visiting http://www.curemeso.org/store . , “Our new store features a variety ... a product is purchased, the Meso Foundation receives a $5.00 donation,” said Beth ...
(Date:7/31/2015)... ... ... There’s no better way to enjoy the summer weather than by being ... meal, making July the most appropriate to be National Hot Dog Month. King Kullen ... the next cookout different than the ones in the past. Celebrate National Hot Dog ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3
... , COLUMBIA, S.C., Aug. 19 ... of semantic technology and knowledge discovery software, announced today that their life ... has surpassed the 200,000 registered user mark . , , ... registered users in less than 18 months is very positive and we ...
... , , , ... healthcare providers are using the OnDemand AP(SM) solution by ... processing costs and cycle time, and improving internal controls and cash ... their invoices electronically, even from suppliers who do not currently support ...
... , MORRISVILLE, Pa., Aug. 19 Managing Myeloma ... eloma.com ) , an accredited educational website for ... goal of the nursing forum is to share insight about day-to-day practice ... advances, and connect with peers. , , ...
... University computer scientist Edmund M. Clarke has received ... Science Foundation,s Expeditions in Computing program to create ... a broad array of fronts, from discovering new ... will combine Model Checking and Abstract Interpretation, two ...
... hypertension that can lead to the formation, dilation, and rupture ... is approximately 5% and one third of those will bleed. ... the University of Edinburgh determined carvedilol was more effective in ... a common treatment used for the past 20 years. ...
... , , WINSTON-SALEM, ... omega-3 fatty acids in red blood cells, is now broadly available ... at-home "finger stick" test. While scientists have long known of the ... the past decade research has proven that the omega-3 fatty acids ...
Cached Medicine News:Health News:Collexis BiomedExperts.com Achieves 200,000 Registered Users 2Health News:Collexis BiomedExperts.com Achieves 200,000 Registered Users 3Health News:Healthcare Providers Employ GHX OnDemand AP(SM) Solution to Automate and Streamline Invoice-to-Payment Process 2Health News:Healthcare Providers Employ GHX OnDemand AP(SM) Solution to Automate and Streamline Invoice-to-Payment Process 3Health News:Healthcare Providers Employ GHX OnDemand AP(SM) Solution to Automate and Streamline Invoice-to-Payment Process 4Health News:Managing Myeloma Website Launches an Interactive Forum for Oncology Nurses, Wins 2009 Gold Hermes Creative Award for Site Overall 2Health News:Carnegie Mellon leads NSF initiative to develop modeling tools for disease and complex systems 2Health News:Carnegie Mellon leads NSF initiative to develop modeling tools for disease and complex systems 3Health News:Carnegie Mellon leads NSF initiative to develop modeling tools for disease and complex systems 4Health News:Carnegie Mellon leads NSF initiative to develop modeling tools for disease and complex systems 5Health News:Study shows carvedilol is effective in preventing variceal bleeding in cirrhotic patients 2Health News:New Omega-3 Blood Test: A Better Predictor of Coronary Heart Disease Than Cholesterol 2Health News:New Omega-3 Blood Test: A Better Predictor of Coronary Heart Disease Than Cholesterol 3Health News:New Omega-3 Blood Test: A Better Predictor of Coronary Heart Disease Than Cholesterol 4
... The Anti-HCV Mixed Titer Performance Panel ... from weak to strong positive for antibodies ... is intended for use by diagnostic manufacturers ... and RNA assays. Comprehensive data from all ...
... POPmesh is a ... that can be used ... pelvic floor procedures, including ... prolapse. Supple yet strong, ...
Suspend® Tutoplast® Processed Fascia Lata is your naturally safe and strong choice for pelvic floor reconstruction. Suspend comes from a dense matrix of collagen bundles and transverse fasc...
... Pelvicol® Acellular Collagen Matrix delivers ... tissue exceptional strength, versatility, and durability ... augments the effectiveness of site-specific defect ... of sterile, biocompatible, crosslinked porcine dermal ...
Medicine Products: